High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE

the PrELUDE Study Group

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


PrELUDE study evaluated daily pre-exposure prophylaxis (PrEP) in high-risk individuals in Australia. This open-label, single-arm study tested participants for HIV/STI and collected behavioural information three-monthly. We report trends over 18 months in medication adherence, side-effects, HIV/STI incidence and behaviour. 320 gay/bisexual men (GBM), 4 women and 3 transgender participants, followed on average 461 days, reported taking seven pills/week on 1,591 (88.5%) occasions and 4-6 pills/week on 153 (8.5%) occasions. No HIV infections were observed. STI incidence was high and stable, while gonorrhoea infections declined from 100.0 to 25.8/100 person-years between 6 and 15 months (p < 0.001). The number of HIV-positive and unknown-status sex partners, and condomless anal intercourse, significantly increased. In this high-risk cohort of mainly GBM, increases in risk behaviours and high STI incidence were not accompanied by HIV infections due to high adherence to daily PrEP. The study informed policy and further PrEP implementation among Australian GBM.

Original languageEnglish
Pages (from-to)1780-1789
Number of pages10
JournalAIDS and Behavior
Issue number7
Publication statusPublished - 15 Jul 2019
Externally publishedYes

Bibliographical note

Funding Information:
PRELUDE Study Team: Mark Bloch, Andrew Carr, Ching (Yvonne) Cheung (study clinical coordinator), Rosalind Foster, Chris Gianacas (clinical data manager), Andrew Grulich, Rebecca Guy, Martin Holt, John Kaldor, Brent Mackie, Kenneth Mayer, John McAllister, Anna McNulty, Dean Murphy, Catriona Ooi, Catherine Pell, Isobel Mary Poynten, Garrett Prestage, Nathan Ryder, David Templeton, Stefanie Vaccher (behavioural data manager), John de Wit, Edwina Wright, and Iryna Zablotska (chief investigator and protocol chair). Participating clinics: Clinic 16 at Royal North Shore Hospital, Holdsworth House Medical Practice, Newcastle Sexual Health Service, RPA Sexual Health, St Vincent’s Hospital HIV Immunology and Infectious Diseases Unit, Sydney Sexual Health Centre, Taylor Square Private Clinic, and Western Sydney Sexual Health Centre. Community partner organisations: ACON (formerly AIDS Council of NSW) and Positive Life NSW.

Funding Information:
Funding The study was funded by the NSW Ministry of Health. Gilead Sciences provided the study medication, Truvada®. The views expressed in this publication do not necessarily represent the position of these organisations.

Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.


  • Behaviour
  • Gay and bisexual men
  • HIV prevention
  • HIV/STI incidence
  • Pre-exposure prophylaxis
  • Sexually transmitted infections
  • Side-effects


Dive into the research topics of 'High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE'. Together they form a unique fingerprint.

Cite this